Skip to main content
Clinical Trials/NCT01343914
NCT01343914
Completed
Not Applicable

Retrospective Study to Determinate the Clinical Phenotype of Patients With Non Squamous NSCLC Treated With First Line Bevacizumab-based Therapy That Reached a Long PFS

Hoffmann-La Roche0 sites118 target enrollmentJune 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Sponsor
Hoffmann-La Roche
Enrollment
118
Primary Endpoint
Progression-free survival (>9 months) according to clinical phenotype
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

This retrospective observational study will analyse demographic, clinical and treatment-related data of patients with non-squamous non-small cell lung cancer (NSCLC) who had reached >/= 9 months of progression-free survival after Avastin (bevacizumab)-based first-line therapy. Data will be collected for approximately 9 months.

Registry
clinicaltrials.gov
Start Date
June 2011
End Date
December 2011
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult patients, \>/= 18 years of age
  • Non-squamous non-small cell lung cancer (NSCLC) treated with first-line Avastin-based therapy
  • Progression-free survival of \>/= 9 months reached

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Progression-free survival (>9 months) according to clinical phenotype

Time Frame: approximately 9 months

Secondary Outcomes

  • Safety: Incidence of adverse events(approximately 9 months)
  • Overall survival(approximately 9 months)

Similar Trials